Skip to main content

Table 1 Patients’ clinical baseline characteristics (n = 17)

From: Novel candidate genes for ECT response prediction—a pilot study analyzing the DNA methylome of depressed patients receiving electroconvulsive therapy

  Whole cohort (n = 17) Responders (n = 10) Non-responders (n = 7)
Demographics
Age in years, mean (±SD; range) 53.9 (± 16.7; 20–76) 57.1 (± 9.7; 43–70) 49.3 (± 23.7; 20–76)
Gender, n (%) Female 10 (58.5%) 6 (60.0%) 4 (57.1%)
Male 7 (41.2%) 4 (40.0%) 3 (42.9%)
Body mass index, mean (±SD; range) 25.9 (± 5.2; 17–39) 28.4 (± 4.8; 23–39)* 22.4 (± 4.5; 17–30)*
Smokers, n (%) Yes 7 (43.8%) 6 (60.0%) 1 (14.3%)
Psychometric characteristics
Age at diagnosis in years, mean (±SD; range) 33.6 (± 17.1; 14–74) 31.3 (± 14.0; 14–53) 36.8 (± 21.5; 18–74)
Current episode in weeks, mean (±SD; range) 36.3 (± 33.6; 3–124) 35.0 (± 38.7; 3–124) 39.0 (± 25.2; 16–68)
BDI, mean (±SD; range) 36.4 (± 10.9; 16–56) 35.3 (± 12.1; 16–56) 38.3 (± 9.2; 24–52)
MADRS, mean (±SD; range) 32.8 (± 10.3; 12–45) 33.8 (± 12.5; 12–45) 31.5 (± 7.4; 24–45)
MMSE, mean (±SD; range) 28.5 (± 2.6; 21–30) 28.0 (± 3.3; 21–30) 29.2 (± 1.3; 27–30)
Psychotic symptoms, n (%) Yes 5 (29.4%) 3 (30.0%) 2 (28.6%)
Suicidality, n (%) Yes 3 (17.6%) 0 (0.0%) 3 (42.9%)
Medication
Antidepressant drugs, n (%) Yes 17 (100.0%) 10 (100.0%) 7 (100.0%)
Benzodiazepines, n (%) Yes 11 (64.7%) 7 (70.0%) 4 (57.1%)
Antipsychotic drugs, n (%) Yes 11 (64.7%) 8 (80.0%) 3 (42.9%)
Lithium, n (%) Yes 3 (17.6%) 1 (10.0%) 2 (28.6%)
Clinical parameters
Leukocytes in × 103/μl, mean (±SD; range) 7.6 (± 2.8; 3.5–12.4) 8.6 (± 2.4; 6.4–12.4) 6.2 (± 2.8; 3.5–12.1)
  1. Clinical baseline characteristics of treatment-resistant depressed patients receiving a course of ECT (whole cohort vs. responders/non-responders), presented as mean (±standard deviation (SD); range (= minimum–maximum)) or quantity (absolute and percentual, n (%))
  2. BDI beck depression inventory, MADRS Montgomery-Åsberg depression rating scale, MMSE mini-mental state examination
  3. *p < 0.05